GET DAILY SIGNALSPrecigen (PGEN) Faces a Steep Climb to $13.65 Target With +97% Upside
Key Takeaways
- The central target of $13.65 is the arithmetic mean of three current, individually verifiable analyst price targets ($11, $12, and $18), rounded to a reader-friendly level.
- At the last regular-session close of $6.94, reaching $13.65 would require a gain of roughly +97% — a very large move that amounts to a near-doubling of the share price.
- The individual targets range from a low of $11 to a high of $18, reflecting genuine disagreement about the pace and durability of the commercial ramp.
- All three target-setting analysts rate the stock Buy or Outperform, but the broader analyst community also includes Neutral views.
- The strongest supporting factors are the commercial launch of the company's first approved therapy, Papzimeos, sharply rising revenue, and a return to quarterly profitability.
- The biggest risks are shareholder dilution, an unprofitable trailing twelve-month result, heavy short interest, and elevated valuation multiples.
- For deeper context, explore Precigen's Major News, Today's Price Move, Forecast, and Earnings pages.
- Discover Trending AI Robots to monitor momentum and signal-driven trading strategies.
Analyst Price Targets and Consensus View
Precigen, Inc. (PGEN) is a Maryland-based gene- and cell-therapy biotechnology company, not an ETF. Its current analyst coverage is thin, which is common for early commercial-stage biotechs. The most recent, individually verifiable 12-month targets are $11 from Citizens JMP (May 2026), $12 from B. Riley Securities (September 2026), and $18 from H.C. Wainwright (October 2026). The arithmetic mean of these three is about $13.67, which rounds to the $13.65 central target used here; the low-to-high range is $11 to $18.
All three firms rate the stock Buy or Outperform, but their reasoning differs in emphasis. H.C. Wainwright raised its target to $18 from $14 after a second-quarter earnings beat, while B. Riley initiated coverage with a Buy, framing Precigen as a newly commercial-stage immuno-oncology company. Separately, data providers such as S&P Global and MarketBeat report slightly different consensus averages (roughly $13.65–$13.67) because they use different analyst sets and time windows. That spread between $11 and $18 underscores how much depends on execution rather than on a single valuation method. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The shares closed the regular session at $6.94 on October 30, 2026, near the middle of a 52-week range of roughly $3.04 to $8.98, and traded sharply lower in after-hours activity — a reminder of the stock's volatility. Reaching $13.65 would require an increase of approximately 97%, a very large move by any standard. The path would likely be driven by sustained commercial revenue growth for Papzimeos (the company's FDA-approved immunotherapy for recurrent respiratory papillomatosis, or RRP), continued margin improvement, and progress in the broader AdenoVerse and UltraCAR-T pipelines. On a trailing basis the company is still unprofitable, so the target rests heavily on forward growth and scale rather than current earnings.
What Could Support a Move Toward the Target
- Commercial traction: Papzimeos generated about $53 million in revenue in the second quarter of 2026, and total quarterly revenue of roughly $55 million rose more than 200% year over year.
- Return to profitability: Precigen reported net income of about $20 million in Q2 2026, its first profitable quarter since 2020.
- Regulatory moat: Papzimeos holds orphan-drug exclusivity as the first approved therapy for adult RRP, and a European marketing application has been submitted.
- Rising estimates: Analysts have repeatedly raised targets and revenue forecasts as launch data has exceeded expectations.
- Pipeline optionality: PRGN-2009 (HPV+ solid tumors) and the UltraCAR-T programs represent longer-dated growth avenues beyond the lead product.
What Could Prevent the Target From Being Reached
- Dilution: Shares outstanding rose about 18% year over year, and the sharp after-hours decline suggests the market is sensitive to additional capital raises.
- Lack of trailing profitability: Trailing twelve-month net income remains deeply negative, and free cash flow is negative.
- Valuation: At roughly 28 times trailing sales and more than 7 times forward sales, expectations are already elevated.
- Short interest: About 13% of shares outstanding are sold short, which can amplify both rallies and sell-offs.
- Competition and execution risk: Rival candidates in RRP and the broader oncology space, plus the inherent uncertainty of a young commercial launch, could slow the ramp.
Technical Levels and Market Structure
The stock sits below its 50-day moving average near $7.22 but above its 200-day moving average near $5.27, a mixed long-term picture. The 52-week range of $3.04 to $8.98 means the prior high near $9 is a meaningful resistance zone on the way to double digits, while the $5 level and the 200-day average represent nearby support. A decisive move above the $9 area could open the door toward the psychological $10 and $12–$13 levels, but those zones remain far from the current price.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though the firms here do not all disclose identical time frames. Investors should watch the company's quarterly earnings report on November 4, 2026, for Papzimeos revenue, gross margins, and any commentary on cash needs and dilution. Additional catalysts include European regulatory decisions, pipeline data readouts, analyst target revisions, and any announcements regarding capital raises or partnership deals. None of these offers a definitive forecast of the share price.
Using AI Signals in My Research
Tickeron's AI Daily Buy/Sell Signals have become a regular part of how I track short-term shifts in names like this. The platform applies AI to scan thousands of stocks and generate signals based on technical and market changes, which helps me stay on top of momentum without constant manual checks. It adds a useful layer when I'm reviewing earnings or pipeline updates.
Final Assessment
The $13.65 central target — the average of three verified analyst price targets — implies roughly a 97% gain from the last close of $6.94, a very large move that would require Precigen to sustain its commercial momentum, convert revenue growth into durable profitability, and fund its plans without excessive dilution. The bull case rests on Papzimeos traction, orphan-drug exclusivity, and a return to quarterly profits, while the bear case emphasizes negative trailing earnings, rich valuation, heavy short interest, and share-count growth. The wide $11-to-$18 target range shows that analysts disagree materially on how fast the launch can scale. The target is a benchmark for what optimistic sell-side models assume, not a guarantee, and the path toward it will be shaped by upcoming earnings, pipeline data, and financing decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PGEN in downward trend: price dove below 50-day moving average on October 15, 2026
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 33 of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 78 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 43 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PGEN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PGEN's RSI Oscillator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 67 of 70 cases where PGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +14.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (43.136) is normal, around the industry mean (3.051). P/E Ratio (-4.907) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology
Advertisement